Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Revance Therapeutics, Inc./ 15-12G

SEC Filing · 15-12G

Revance Therapeutics, Inc.

SEC Filing

Filed Feb 18, 2025Accepted Feb 18, 2025, 1:07 AM ESTCIK 1479290Accession 0001193125-25-028024
View company →Permanent SEC source ↗
Share

Recent company filings

  1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding Revance Therapeutics, Inc.May 15, 2025
  2. SCHEDULE 13G/A - filed by JPMORGAN CHASE & CO regarding Revance Therapeutics, Inc.Mar 6, 2025
  3. SCHEDULE 13G/A - filed by Palo Alto Investors LP regarding Revance Therapeutics, Inc.Feb 13, 2025
  4. S-8 POS filingFeb 12, 2025
  5. S-8 POS filingFeb 12, 2025

As-filed source

Primary evidence
As filedOpen full document ↗